Position of the Transparency Council – Zolgensma (onasemnogene abeparvovec)

At its meeting on 5 August 2024, the Transparency Council adopted position No. 80/2024 on the evaluation of the drug Zolgensma (onasemnogene abeparvovec) under the drug program: “Treatment of patients with spinal muscular atrophy (ICD-10: G12.0, G12.1)”

Publication of the position >>